 Fibroblast growth factor 23 ( FGF23) has appeared as a hormone that is massively elevated in patients with chronic kidney disease. Whether FGF23 is a risk factor that associates with cardiac pathologies and cardiovascular mortality , as suggested by a variety of clinical studies , or additionally acts as a causative factor that induces cardiac injury , as more recently indicated by cell culture and animal studies , is under debate and the center of many ongoing experimental studies.